Brief: Landos Biopharma's Phase 2 Data Of Omilancor In Ulcerative Colitis Accepted For Oral Presentation
22/07/2021 12:09
July 22 (Reuters) - Landos Biopharma Inc LABP.O :
* LANDOS BIOPHARMA'S PHASE 2 DATA OF OMILANCOR IN ULCERATIVE
COLITIS ACCEPTED FOR ORAL PRESENTATION AT UNITED EUROPEAN
GASTROENTEROLOGY WEEK 2021
Source text for Eikon: ID:nGNX8gv8T0
Further company coverage: LABP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Landos Biopharma
See all newsLandos Biopharma Inc expected to post a loss of 100 cents a share - Earnings Preview
Deals of the day-Mergers and acquisitions
U.S. STOCKS ON THE MOVE-Super Micro, Micron Technology, Navios Maritime
U.S. STOCKS ON THE MOVE-Landos Biopharma, Foot Locker, US energy sector
Brief: AbbVie To Acquire Landos Biopharma